NCT01573780View on ClinicalTrials.gov

Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2013

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

Smac mimetic TL32711

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

PROCEDURE

biopsy

Optional correlative studies

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

19107

Thomas Jefferson University, Philadelphia

Sponsors
All Listed Sponsors
collaborator

TetraLogic Pharmaceuticals

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT01573780 - Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter